China dermatology New Drug Alliance was established

Beijing News (Chen De) The founding conference of China dermatology New Drug Alliance and the first dermatology New Drug Clinical Research Summit Forum were held recently in Beijing. The alliance aims to strengthen the collaborative innovation and scientific and technological innovation of clinical research, new drug research and development, and achievement transformation in dermatology, promote the linkage of "government, industry, university, research and medicine", so as to promote the high-quality development and global cooperation of dermatology innovative drug industry, and benefit Chinese and global dermatology patients

Beijing News (Chen De) The founding conference of China dermatology New Drug Alliance and the first dermatology New Drug Clinical Research Summit Forum were held recently in Beijing. The alliance aims to strengthen the collaborative innovation and scientific and technological innovation of clinical research, new drug research and development, and achievement transformation in dermatology, promote the linkage of "government, industry, university, research and medicine", so as to promote the high-quality development and global cooperation of dermatology innovative drug industry, and benefit Chinese and global dermatology patients.

In 2021, China approved a new drug for skin and facial features in clinical trials, ranking second in chemical medicine and third in biological preparations. In 2022, there will be 328 clinical trials of new drugs in dermatology. Against this background, the establishment of China dermatology New Drug Alliance is just in time. The Alliance has set up a platform for innovative drug research and development and academic exchange of production, learning, research and use. Through timely understanding of clinical needs, exchange of research and development information, and putting forward policy recommendations, the Alliance has continuously promoted the innovative development of patient centered dermatology drugs.

The Alliance has accepted more than 50 directors and deputy directors of dermatology departments of major hospitals in China and leaders of clinical trial institution offices, and 28 enterprises and investment institutions have joined the Alliance. "Today, with the rapid development of new dermatology drugs in China, it is very necessary to establish the China dermatology New Drug Alliance." Zhang Jianzhong, co chairman of the Alliance, said that the Alliance will give full play to the five major roles of the platform, namely, information exchange, academic services, resource gathering, industry think tanks and international leadership, so as to improve China's innovation and scientific research transformation capacity.

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])